• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

B-po05-144 comparing sodium glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset atrial fibrillation and ischemic stroke
Given the susceptibility of patients with type 2 diabetes mellitus towards cerebrovascular complications, there is increasing research on the cerebrovascular-protective effects of novel anti-diabetic agents. However, few studies have compared sodium glucose cotransporter-2 inhibitor (SGLT2I) and dipeptidyl peptidase-4 inhibitor (DPP4I) in their effects on stroke and atrial fibrillation (AF).
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Sharen Lee, Jiandong Zhou, Xiansong Wang, Carlin Chang, Tong Liu, Dong Chang, Wing Tak Wong, William K.K. Wu, Bernard M.Y. Cheung, Gary Tse, Qingpeng Zhang Source Type: research

Anti-diabetic drugs for preventing atrial fibrillation: a new revolution?
Type 2 diabetes mellitus (DM) and atrial fibrillation (AF) are two of the great epidemics of our time. DM affects and estimated 8.5% of adults in the US1, and is associated with an increased risk of cardiovascular events, including AF.2 AF in turn affects an estimated up to 12.5% of adults over age 65 years in the US, decreases quality of life and increases the risks of heart failure, stroke and death 3,4. In 2015, the EMPA-REG OUTCOME randomized controlled trial (RCT), assessing a sodium glucose co-transporter 2 inhibitor (SGLT-2i), sparked interest in the therapeutic potential for oral anti-diabetic agents to reduce card...
Source: Heart Rhythm - April 7, 2021 Category: Cardiology Authors: William F. McIntyre, Jeff S. Healey Source Type: research

Antidiabetic drugs for preventing atrial fibrillation: A new revolution?
Type 2 diabetes mellitus (DM) and atrial fibrillation (AF) are 2 of the great epidemics of our time. DM affects an estimated 8.5% of adults in the United States1 and is associated with an increased risk of cardiovascular events, including AF.2 AF in turn affects up to an estimated 12.5% of adults older than 65 years in the United States, decreases quality of life, and increases the risks of heart failure, stroke, and death.3,4 In 2015, the EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) randomized controlled trial (RCT), which assessed the sodium glucose c...
Source: Heart Rhythm - April 7, 2021 Category: Cardiology Authors: William F. McIntyre, Jeff S. Healey Tags: Editorial Commentary Source Type: research

Who is at risk of atrial fibrillation?
Atrial fibrillation (AF) is a common cause of stroke, with prevalence increasing alongside the aging of our population [1]. Increasing age, hypertension, obesity, heart failure, sleep apnea, diabetes, coronary disease, chronic kidney disease and smoking account for much of the global risk of AF [2 3]. Incident AF is also predicted by both rare and common genetic variants, many of which encode for cardiac structural and electrical proteins, as well as by more complex heritable traits such as height, obesity and race [4-6].
Source: Heart Rhythm - February 24, 2021 Category: Cardiology Authors: Jeff S. Healey, Jason D. Roberts, Thalia S. Field Source Type: research

EP News: Clinical
Diederichsen et  al (J Am Coll Cardiol 2019;74:2771, PMID 31779791) evaluated the natural history of subclinical atrial fibrillation (AF) in at-risk patients from the general population. The authors studied 590 individuals ≥70 years of age with ≥1 of hypertension, diabetes, previous stroke, or heart failure; w ithout a history of AF; and with long-term implantable loop recorder monitoring. End points included AF burden, AF progression, symptoms, and heart rate during AF. In a total of 685,445 monitoring days, AF lasting ≥6 minutes was detected in 205 participants (35%).
Source: Heart Rhythm - January 20, 2020 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research

The metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic
The prevalence of atrial fibrillation (AF) and AF-related stroke is set to increase dramatically in coming decades, with developing regions such as Latin America experiencing the greatest impact. These trends are primarily driven by aging populations and by the increasing prevalence of the metabolic syndrome. The metabolic syndrome describes an association between diabetes, hypertension, obesity, and dyslipidemia and an increased risk of cardiovascular disease. It is in large part the result of unbalanced diet and sedentary lifestyle.
Source: Heart Rhythm - June 30, 2015 Category: Cardiology Authors: Reza Hajhosseiny, Gareth K. Matthews, Gregory Y.H. Lip Tags: Contemporary Review Source Type: research

The Metabolic Syndrome, Atrial Fibrillation and Stroke: Tackling An Emerging Epidemic
The prevalence of atrial fibrillation (AF) and AF-related stroke is set to increase dramatically in coming decades, with developing regions such as Latin America experiencing the greatest impact. These trends are primarily driven by aging populations and by the increasing prevalence of metabolic syndrome. Metabolic syndrome describes an association between diabetes, hypertension, obesity, dyslipidaemia and an increased risk of cardiovascular disease. It is in large part the result of unbalanced diet and sedentary lifestyle.
Source: Heart Rhythm - June 30, 2015 Category: Cardiology Authors: Reza Hajhosseiny, Gareth K. Matthews, Gregory YH Lip Tags: CRV Source Type: research

Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic
The prevalence of atrial fibrillation (AF) and AF-related stroke is set to increase dramatically in coming decades, with developing regions such as Latin America experiencing the greatest impact. These trends are primarily driven by aging populations and by the increasing prevalence of the metabolic syndrome. The metabolic syndrome describes an association between diabetes, hypertension, obesity, and dyslipidemia and an increased risk of cardiovascular disease. It is in large part the result of unbalanced diet and sedentary lifestyle.
Source: Heart Rhythm - June 30, 2015 Category: Cardiology Authors: Reza Hajhosseiny, Gareth K. Matthews, Gregory Y.H. Lip Tags: Contemporary Review Source Type: research

Glycated Hemoglobin and Risk of First Episode Stroke in Diabetic Patients with Atrial Fibrillation: A Cohort Study
Diabetes is associated with increased risk of stroke in patients with atrial fibrillation. Whether glycemic control, evaluated by glycated hemoglobin, affects the risk of stroke in diabetic patients with atrial fibrillation remains unknown.
Source: Heart Rhythm - January 19, 2015 Category: Cardiology Authors: W. Saliba, O. Barnett-Griness, M. Elias, G. Rennert Source Type: research

Eastern promises: Additive role of metabolic syndrome for thromboembolic risk stratification in Taiwanese atrial fibrillation patients
The key to prevention of stroke and other thromboembolic (TE) events in atrial fibrillation (AF) patients is effective risk stratification. Several schemes have been developed that use a combination of factors found to be associated with higher occurrence of TE events. Among the various risk stratification schemes, the CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes, and prior history of stroke) scoring system is the most popular. Although the simplicity of this scoring system has resulted in its wide adoption, a major criticism has been its inability to consistently identify a truly low-risk grou...
Source: Heart Rhythm - December 6, 2013 Category: Cardiology Authors: Sanjay Dixit, Vinay Kini Tags: Editorial Commentary Source Type: research

Platelet-derived growth factor: A promising therapeutic target for atrial fibrillation
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is characterized by substantial electrophysiological and structural changes. AF is associated with an increased risk of stroke, heart failure, and overall mortality. The risk of developing AF increases with age and with other risk factors such as diabetes and underlying heart disease. Currently, the therapeutic options for the treatment of AF have moderate effectiveness, and side effects, including proarrhythmic events, can often be encountered. The limited effectiveness of antiarrhythmic drugs available for the management of AF is especially proble...
Source: Heart Rhythm - April 8, 2013 Category: Cardiology Authors: Céline Fiset Tags: Editorial Commentary Source Type: research

MicroRNAs emerging as mediators of remodeling with atrial fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is now established as an independent risk factor for stroke. Moreover, a concomitant diagnosis of AF greatly complicates treatment for a number of disease processes such as diabetes and congestive heart failure. Given the recognized additional burden that AF places on the health-care system, significant research has been performed in an attempt to delineate mechanisms that contribute to AF initiation as well as progression. Understandably, there is an extensive body of research that has identified abnormalities in ionic channels/electrogenic processes that ...
Source: Heart Rhythm - March 25, 2013 Category: Cardiology Authors: Adam W. Akerman, Rupak Mukherjee Tags: Editorial Commentary Source Type: research